Parkinson Diseasealpha-SynucleinAntiparkinson AgentsPsychiatric Status Rating ScalesParkinsonian DisordersLevodopaGlucosylceramidaseParkinson Disease, SecondaryDeep Brain StimulationLewy BodiesSubstantia NigraSeverity of Illness IndexSubthalamic NucleusGait Disorders, NeurologicDopamineLewy Body Disease1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineReproducibility of ResultsMultiple System AtrophyDopaminergic NeuronsPostural BalanceBrief Psychiatric Rating ScaleNeuropsychological TestsHypokinesiaOxidopamineMPTP PoisoningDementiaPutamenSupranuclear Palsy, ProgressivePsychometricsEssential TremorDance TherapyQuestionnairesNeurodegenerative DiseasesBrainGaitMovement DisordersGlobus PallidusTreatment OutcomePain MeasurementDisability EvaluationCognition DisordersUbiquitin-Protein LigasesNeurologic ExaminationPedunculopontine Tegmental NucleusDouble-Blind MethodNeuronsCarbidopaAge of OnsetREM Sleep Behavior DisorderGaucher DiseaseQuality of LifeTyrosine 3-MonooxygenaseActivities of Daily LivingDyskinesiasPergolideCorpus StriatumApathybeta-SynucleinOncogene ProteinsDepressionNerve DegenerationDepressive Disorder, MajorCase-Control StudiesAlzheimer DiseasePrimary DysautonomiasGenetic Predisposition to DiseaseAnalysis of VarianceDyskinesia, Drug-InducedMental Status ScheduleTime FactorsManebFollow-Up StudiesMutationProspective StudiesOlfaction DisordersMesencephalonSleep Arousal DisordersDepressive DisorderBenzothiazolesDopamine Plasma Membrane Transport ProteinsMotor SkillsCognitionPositron-Emission TomographyNeuroprotective AgentsMitochondriaSynucleinsObserver Variation1-Methyl-4-phenylpyridiniumCohort StudiesTremorPilot ProjectsMagnetic Resonance ImagingDopamine AgentsAntidepressive AgentsHallucinationsTropanesStereotaxic TechniquesDopamine AgonistsPsychomotor Performance